Calcitonin oral - Biocon/Seachaid Pharmaceuticals

Drug Profile

Calcitonin oral - Biocon/Seachaid Pharmaceuticals

Alternative Names: CT 025; NCT-025; Oratonin

Latest Information Update: 21 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biocon
  • Developer Seachaid Pharmaceuticals
  • Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Calcitonin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Postmenopausal osteoporosis

Most Recent Events

  • 02 Apr 2004 The Synerobex joint venture between Nobex Corporation and Elan Corporation has been dissolved; Oratonin™ is now owned solely by Nobex
  • 24 Mar 2004 Oratonin™ is available for licensing worldwide (
  • 17 Apr 2002 Phase-I clinical trials in Postmenopausal osteoporosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top